Augenärztliche Screening-Untersuchung bei Frühgeborenen (S2k-Level, AWMF-Leitlinien-Register-Nr. 024/010, März 2020)

Rolf F. Maier; Helmut Hummler; Ulrich Kellner; Tim U. Krohne; Burkhard Lawrenz; Birgit Lorenz; Barbara Mitschdörfer; Claudia Roll; Andreas Stahl

doi:10.1055/a-1248-0649

Zeitschrift für Geburtshilfe und Neonatologie, Table of Contents

Z Geburtshilfe Neonatol 2021; 225(01): 19-33
DOI: 10.1055/a-1248-0649

Leitlinie

Augenärztliche Screening-Untersuchung bei Frühgeborenen (S2k-Level, AWMF-Leitlinien-Register-Nr. 024/010, März 2020)

Gemeinsame Empfehlung von Deutsche Ophthalmologische Gesellschaft (DOG), Retinologische Gesellschaft (RG), Berufsverband der Augenärzte Deutschlands (BVA), Deutsche Gesellschaft für Kinder- und Jugendmedizin (DGKJ), Berufsverband der Kinder- und Jugendärzte e.V. (BVKJ), Bundesverband „Das frühgeborene Kind“ e.V., Gesellschaft für Neonatologie und Pädiatrische Intensivmedizin (GNPI)

Rolf F. Maier^*

¹Zentrum für Kinder- und Jugendmedizin Marburg, Universitätsklinikum Gießen und Marburg GmbH, Standort Marburg, Philipps-Universität Marburg

,

Helmut Hummler

²Division of Neonatology, Sidra Medicine, Doha, Qatar

,

Ulrich Kellner

³Augenzentrum Siegburg, MVZ Augenärztliches Diagnostik- und Therapiecentrum Siegburg GmbH

,

Tim U. Krohne

⁴Universitäts-Augenklinik Bonn

,

Burkhard Lawrenz

⁵Privatpraxis für Kinder- und Jugendmedizin Dr. med. Burkhard Lawrenz, Arnsberg

,

Birgit Lorenz

⁶Klinik und Poliklinik für Augenheilkunde, Universitätsklinikum Gießen und Marburg GmbH, Standort Gießen, Justus-Liebig-Universität Gießen

,

Barbara Mitschdörfer

⁷Bundesverband „Das frühgeborene Kind“ e.V.

,

Claudia Roll

⁸Abteilung für Neonatologie, Pädiatrische Intensivmedizin, Schlafmedizin, Vestische Kinder- und Jugendklinik Datteln, Universität Witten/Herdecke

,

Andreas Stahl

⁹Klinik und Poliklinik für Augenheilkunde, Universitätsmedizin Greifswald

› Author Affiliations

Abstract

Full Text

References

Literatur
1 Beken S, Dilli D, Fettah ND. et al. The influence of fish-oil lipid emulsions on retinopathy of prematurity in very low birth weight infants: a randomized controlled trial. Early Hum Dev 2014; 90: 27-31
2 Bharwani SK, Dhanireddy R. Systemic fungal infection is associated with the development of retinopathy of prematurity in very low birth weight infants: a meta-review. J Perinatol 2008; 28: 61-66
3 BOOST II United Kingdom Collaborative Group; BOOST II Australia Collaborative Group; BOOST II New Zealand Collaborative Group, Stenson BJ, Tarnow-Mordi WO, Darlow BA. et al. Oxygen saturation and outcomes in preterm infants. N Engl J Med 2013; 368: 2094-2104
4 Campbell JP, Kalpathy-Cramer J, Erdogmus D. et al. Imaging and Informatics in Retinopathy of Prematurity Research Consortium Plus Disease in Retinopathy of Prematurity: A continuous spectrum of vascular abnormality as a basis of diagnostic variability. Ophthalmology 2016; 123: 2338-2344
5 Chen SN, Lian I, Hwang YC. et al. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab. Retina 2015; 35: 667-674
6 Clemens S, Eckardt C, Gerding H. et al. (Arbeitsgruppe zur Erstellung von Leitlinien zur augenärztlichen Screening-Untersuchung von Frühgeborenen). Augenärztliche Screening-Untersuchung von Frühgeborenen. Ophthalmologe 1999; 96: 257-263
7 Connolly BP, Ng EY, McNamara JA. et al. A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 2. Refractive outcome. Ophthalmology 2002; 109: 936-941
8 Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Arch Ophthalmol 1988; 106: 471-479
9 Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity. Snellen visual acuity and structural outcome at 5 1/2 years after randomization. Arch Ophthalmol 1996; 114: 417-424
10 Cryotherapy for Retinopathy of Prematurity Cooperative Group Multicenter Trial of Cryotherapy for Retinopathy of Prematurity: ophthalmological outcomes at 10 years. Arch Ophthalmol 2001; 119: 1110-1118
11 Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity: natural history ROP: ocular outcome at 5(1/2) years in premature infants with birth weights less than 1251 g. Arch Ophthalmol 2002; 120: 595-599
12 Czernik C, Metze B, Müller C. et al. Urinary N-terminal B-type natriuretic peptide predicts severe retinopathy of prematurity. Pediatrics 2011; 128: e545-e549
13 Dempsey E, McCreery K. Local anaesthetic eye drops for prevention of pain in preterm infants undergoing screening for retinopathy of prematurity. Cochrane Database Syst Rev 2011; CD007645
14 Di Fiore JM, Bloom JN, Orge F. et al. A higher incidence of intermittent hypoxemic episodes is associated with severe retinopathy of prematurity. J Pediatr 2010; 157: 69-73
15 Ells AL, Wesolosky JD, Ingram AD. et al. Low-dose ranibizumab as primary treatment of posterior type I retinopathy of prematurity. Can J Ophthalmol 2017; 52: 468-474
16 Fierson WM. American Academy of Pediatrics Section on Ophthalmology; American Academy of Ophthalmology; American Association for Pediatric Ophthalmology and Strabismus; American Association of Certified Orthoptists. Screening examination of premature infants for retinopathy of prematurity. Pediatrics 2018; 142: e20183061
17 Geloneck MM, Chuang AZ, Clark WL. et al. BEAT-ROP Cooperative Group. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. JAMA Ophthalmol 2014; 132: 1327-1333
18 Hard AL, Hellström A. On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment – a review. Acta Paediatr 2011; 100: 1523-1527
19 Harder BC, von Baltz S, Jonas JB. et al. Intravitreal low-dosage bevacizumab for retinopathy of prematurity. Acta Ophthalmol 2014; 92: 577-581
20 Hartnett ME, Morrison MA, Smith S. et al. Genomics Subcommittee. Genetic variants associated with severe retinopathy of prematurity in extremely low birth weight infants. Invest Ophthalmol Vis Sci 2014; 55: 6194-6203
21 Hellström A, Ley D, Hansen-Pupp I. et al. Insulin-like growth factor 1 has multisystem effects on foetal and preterm infant development. Acta Paediatr 2016; 105: 576-586
22 Hittner HM, Hirsch NJ, Rudolph AJ. Assessment of gestational age by examination of the anterior vascular capsule of the lens. J Pediatr 1977; 91: 455-458
23 Holmström GE, Hellström A, Jakobsson PG. et al. Swedish national register for retinopathy of prematurity (SWEDROP) and the evaluation of screening in Sweden. Arch Ophthalmol 2012; 130: 1418-1424
24 Holmström G, Hellström A, Jakobsson P. et al. Evaluation of new guidelines for ROP screening in Sweden using SWEDROP – a national quality register. Acta Ophthalmol 2015; 93: 265-268
25 Holmström G, Hellström A, Gränse L. et al. New modifications of Swedish ROP guidelines based on 10-year data from the SWEDROP register. Br J Ophthalmol 2020; 104: 943-949
26 Hu J, Blair MP, Shapiro MJ. et al. Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol 2012; 130: 1000-1006
27 Huang Q, Zhang Q, Fei P. et al. Ranibizumab Injection as Primary Treatment in Patients with Retinopathy of Prematurity: Anatomic Outcomes and Influencing Factors. Ophthalmology 2017; 124: 1156-1164
28 Hughes S, Yang H, Chan-Ling T. Vascularization of the human fetal retina: roles of vasculogenesis and angiogenesis. Invest Ophthalmol Vis Sci 2000; 41: 1217-1228
29 International Committee for the Classification of Retinopathy of Prematurity. An international classification of retinopathy of prematurity revisited. Arch Ophthalmol 2005; 123: 991-999
30 IQTIG – Institut für Qualitätssicherung und Transparenz im Gesundheitswesen. Bundesauswertung zum Erfassungsjahr 2017. Neonatologie. Qualitätsindikatoren. https://iqtig.org/downloads/auswertung/2017/neo/QSKH_NEO_2017_BUAW_V02_2018-08-01.pdf
31 Isaac M, Mireskandari K, Tehrani N. Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser. J AAPOS 2015; 19: 140-144
32 Jandeck C, Kellner U, Heimann H. et al. Koagulationstherapie der Frühgeborenenretinopathie: Vergleich der anatomischen und funktionellen Ergebnisse nach Laser- oder Kryokoagulation. Ophthalmologe 2005; 102: 33-38
33 Jandeck C, Kellner U, Lorenz B. et al. (Arbeitsgruppe der Retinologischen Gesellschaft zur Erstellung der Leitlinie zur augenärztlichen Screening-Untersuchung von Frühgeborenen). Leitlinie zur augenärztlichen Screening-Untersuchung von Frühgeborenen. Klin Monatsbl Augenheilkd 2008; 225: 123-30
34 Jang SY, Choi KS, Lee SJ. Delayed-onset retinal detachment after an intravitreal injection of ranibizumab for zone 1 plus retinopathy of prematurity. J AAPOS 2010; 14: 457-459
35 Jefferies AL. Canadian Paediatric Society, Fetus and Newborn Committee. Retinopathy of prematurity: An update on screening and management. Paediatr Child Health 2016; 21: 101-108
36 Jin E, Yin H, Li X. et al. Short-term outcomes after intravitreal injections of conbercept versus ranibizumab for the treatment of retinopathy of prematurity. Retina 2018; 38: 1595-1604
37 Kennedy KA, Wrage LA, Higgins RD. et al. SUPPORT Study Group of the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Evaluating retinopathy of prematurity screening guidelines for 24- to 27-week gestational age infants. J Perinatol 2014; 34: 311-318
38 Kennedy KA, Mintz-Hittner HA. BEAT-ROP Cooperative Group. Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity. J AAPOS 2018; 22: 61-65.e1
39 Kong L, Bhatt AR, Demny AB. et al. Pharmacokinetics of Bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity. Invest Ophthalmol Vis Sci 2015; 56: 956-961
40 Krohne TU. Frühgeborenenretinopathie: Aktuelle Entwicklungen in Therapie und Epidemiologie. Ophthalmologe 2018; 115: 454-455
41 Larsen PP, Bründer MC, Petrak M. et al. Frühgeborenenretinopathie-Screening: Trends über die vergangenen 5 Jahre an zwei deutschen Universitätskliniken. Ophthalmologe 2018; 115: 469-475
42 Larsen PP, Kipfmueller F, Holz FG. et al. Retinal findings in neonates with congenital diaphragmatic hernia and extracorporeal membrane oxygenation. J Pediatr Surg 2020; 55: 1292-1295
43 Ley D, Hallberg B, Hansen-Pupp I. et al. study team. rhIGF-1/rhIGFBP-3 in Preterm Infants: A phase 2 randomized controlled trial. J Pediatr 2019; 206: 56-65.e8
44 Lloyd J, Askie L, Smith J. et al. Supplemental oxygen for the treatment of prethreshold retinopathy of prematurity. Cochrane Database Syst Rev 2003; CD003482
45 Löfqvist C, Anderson E, Sigurdsson J. et al. Longitudinal postnatal weight and Insulin-like Growth Factor I measurements in prediction of retinopathy of prematurity. Arch Ophthalmol 2006; 124: 1711-1718
46 Lorenz B, Spasovska K, Elflein H. et al. Wide-field digital imaging based telemedicine for screening for acute retinopathy of prematurity (ROP). Six-year results of a multicentre field study. Graefes Arch Clin Exp Ophthalmol 2009; 247: 1251-1262
47 Lorenz B, Stieger K, Jäger M. et al. Retinal vascular development with 0.312 mg intravitreal Bevacizumab to treat severe posterior retinopathy of prematurity: A longitudinal fluorescein angiographic study. Retina 2017; 37: 97-111
48 Lundgren P, Kistner A, Andersson EM. et al. Low birth weight is a risk factor for severe retinopathy of prematurity depending on gestational age. PLoS One 2014; 9: e109460
49 Lundgren P, Lundberg L, Hellgren G. et al. Aggressive posterior retinopathy of prematurity is associated with multiple infectious episodes and thrombocytopenia. Neonatology 2016; 111: 79-85
50 Manzoni P, Stolfi I, Pedicino R. et al. Italian Task Force for the Study and Prevention of Neonatal Fungal Infections, Italian Society of Neonatology. Human milk feeding prevents retinopathy of prematurity (ROP) in preterm VLBW neonates. Early Hum Dev 2013; 89 Suppl 1: 64-68
51 Miller MM, Revenis ME, Lai MM. et al. Risk and clinical course of retinopathy of prematurity in 78 infants of gestational age 22–25 weeks. J AAPOS 2014; 18: 266-270
52 Mintz-Hittner HA, Kennedy KA, Chuang AZ. BEAT-ROP Cooperative Group Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011; 364: 603-615
53 Mintz-Hittner HA, Geloneck MM, Chuang AZ. Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy. Ophthalmology 2016; 123: 1845-1855
54 Morin J, Luu TM, Superstein R. et al. Canadian Neonatal Network and the Canadian Neonatal Follow-Up Network Investigators. Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity. Pediatrics 2016; 137: e20153218
55 Movsas TZ, Spitzer AR, Gewolb IH. Trisomy 21 and risk of retinopathy of prematurity. Pediatrics 2015; 136: e441-e447
56 Ng EY, Connolly BP, McNamara JA. et al. A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 1. Visual function and structural outcome. Ophthalmology 2002; 109: 928-934
57 Ortega-Molina JM, Anaya-Alaminos R, Uberos-Fernández J. et al. Genetic and environmental influences on retinopathy of prematurity. Mediators Inflamm 2015; 2015: 764159
58 Palmer EA, Flynn JT, Hardy RJ. et al. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Incidence and early course of retinopathy of prematurity. Ophthalmology 1991; 98: 1628-1640
59 Paysse EA, Lindsey JL, Coats DK. et al. Therapeutic outcomes of cryotherapy versus transpupillary diode laser photocoagulation for threshold retinopathy of prematurity. J AAPOS 1999; 3: 234-240
60 Photographic Screening for Retinopathy of Prematurity (Photo-ROP) Cooperative Group. The photographic screening for retinopathy of prematurity study (photo-ROP). Primary outcomes. Retina 2008; 28: 47-54
61 Pillai Riddell RR, Racine NM, Gennis HG. et al. Non-pharmacological management of infant and young child procedural pain. Cochrane Database Syst Rev 2015; CD006275
62 Reynolds JD, Dobson V, Quinn GE. et al. CRYO-ROP and LIGHT-ROP Cooperative Study Groups. Evidence-based screening criteria for retinopathy of prematurity: natural history data from the CRYO-ROP and LIGHT-ROP studies. Arch Ophthalmol 2002; 120: 1470-1476
63 Robinson J, Fielder AR. Pupillary diameter and reaction to light in preterm neonates. Arch Dis Child 1990; 65: 35-38
64 Salcone EM, Johnston S, VanderVeen D. Review of the use of digital imaging in retinopathy of prematurity screening. Semin Ophthalmol 2010; 25: 214-217
65 Salman AG, Said AM. Structural, visual and refractive outcomes of intravitreal aflibercept injection in high-risk prethreshold type 1 retinopathy of prematurity. Ophthalmic Res 2015; 53: 15-20
66 Sankar MJ, Sankar J, Mehta M. et al. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. Cochrane Database Syst Rev 2016; CD009734
67 Saugstad OD, Aune D. Optimal oxygenation of extremely low birth weight infants: a meta-analysis and systematic review of the oxygen saturation target studies. Neonatology 2014; 105: 55-63
68 Schaffer DB, Palmer EA, Plotsky DF. et al. Prognostic factors in the natural course of retinopathy of prematurity. Ophthalmology 1993; 100: 230-237
69 Schmidt B, Whyte RK, Asztalos EV. et al. Canadian Oxygen Trial (COT) Group. Effects of targeting higher vs. lower arterial oxygen saturations on death or disability in extremely preterm infants: a randomized clinical trial. JAMA 2013; 309: 2111-2120
70 Smith LE, Shen W, Perruzzi C. et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularisation by insulin-like growth factor-1 receptor. Nat Med 1999; 5: 1390-1395
71 Spiegler J, Preuß M, Gebauer C. et al. German Neonatal Network (GNN). Does breastmilk influence the development of bronchopulmonary dysplasia?. J Pediatr 2016; 169: 76-80
72 Stahl A, Krohne TU, Eter N. et al. Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity (CARE-ROP) Study Group. Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity: A Randomized Clinical Trial. JAMA Pediatr 2018; 172: 278-286
73 Stahl A, Lepore D, Fielder A. et al. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. Lancet 2019; 394: 1551-1559
74 Supplemental Therapeutic Oxygen for Prethreshold Retinopathy Of Prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes. Pediatrics 2000; 105: 295-310
75 SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network, Carlo WA, Finer NN, Walsh MC. et al. Target ranges of oxygen saturation in extremely preterm infants. N Engl J Med 2010; 362: 1959-1969
76 The Committee for the Classification of Retinopathy of Prematurity. An international classification of retinopathy of prematurity. Arch Ophthalmol 1984; 102: 1130-1134
77 The Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 2003; 121: 1684-1696
78 The International Committee for the Classification of the Late Stages of Retinopathy of Prematurity. An international classification of retinopathy of prematurity. II. The classification of retinal detachment. Arch Ophthalmol 1987; 105: 906-912
79 The Laser ROP Study Group. Laser therapy for retinopathy of prematurity. Arch Ophthalmol 1994; 112: 154-156
80 VanderVeen DK, Melia M, Yang MB. et al. Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity: A report by the American Academy of Ophthalmology. Ophthalmology 2017; 124: 619-633
81 van Sorge AJ, Schalij-Delfos NE, Kerkhoff FT. et al. Reduction in screening for retinopathy of prematurity through risk factor adjusted inclusion criteria. Br J Ophthalmol 2013; 97: 1143-1147
82 Vinekar A, Hegde K, Gilbert C. et al. Do platelets have a role in the pathogenesis of aggressive posterior retinopathy of prematurity?. Retina 2010; 30: 20-23
83 Wallace DK, Kraker RT, Freedman SF. et al. Pediatric Eye Disease Investigator Group (PEDIG). Assessment of lower doses of intravitreous Bevacizumab for retinopathy of prematurity: A Phase 1 dosing study. JAMA Ophthalmol 2017; 135: 654-656
84 Weaver DT. Telemedicine for retinopathy of prematurity. Curr Opin Ophthalmol 2013; 24: 425-431
85 Wilkinson AR, Haines L, Head K. et al. UK retinopathy of prematurity guideline. Early Hum Dev 2008; 84: 71-74
86 Wong RK, Hubschman S, Tsui I. Reactivation of retinopathy of prematurity after ranibizumab treatment. Retina 2015; 35: 675-680
87 Wu C, Löfqvist C, Smith LE. et al. WINROP Consortium. Importance of early postnatal weight gain for normal retinal angiogenesis in very preterm infants: a multicenter study analyzing weight velocity deviations for the prediction of retinopathy of prematurity. Arch Ophthalmol 2012; 130: 992-999
88 Wu LH, Yang YH, Lin CH. et al. Hypotension associated with intravitreal bevacizumab therapy for retinopathy of prematurity. Pediatrics 2016; 137: e20152005
89 Wu WC, Shih CP, Lien R. et al. Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity. Retina 2017; 37: 694-701